Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan’s 1st Orphan Regenerative Medicine Status Given to Skin-Derived Cell Sheet
December 1, 2014
- 13 APIs/23 Products Including Remicade Biosimilar Added to NHI Price List
November 28, 2014
- MHLW Warns of Hyperbilirubinemia in Patients on Sovriad
November 27, 2014
- Panel Gives Green Light to Draft Report Calling for Legal Regulations for Clinical Research
November 27, 2014
- Cabinet OKs Regenerative Medicine Guidelines
November 26, 2014
- New Pharma Law Takes Effect to Up the Ante for Safety
November 26, 2014
- Debates on Yearly NHI Price Cuts Put on Hold as Attention Turns to Election
November 26, 2014
- Chuikyo OKs Requirements for Hospitals Offering Mixed Care in Economic Zones
November 25, 2014
- MHLW Designates 6 APIs as Orphan Drugs
November 25, 2014
- PAFSC First Committee Backs Approval of Takeda’s Vonoprazan
November 25, 2014
- IGDRP to Extend Activities for 2 More Years with Aim of Harmonizing Generic Drug Review
November 25, 2014
- MHLW Orders Revision of Package Insert for Reminyl
November 25, 2014
- MHLW Issues Notification on Infection Risk Reporting for Regenerative Medicines
November 21, 2014
- Potential Risk of Narcolepsy for Belsomra Should Be Thoroughly Communicated: Chuikyo
November 21, 2014
- Don’t Use Long-Listed Drugs, Dispense Generics: LDP Project Team
November 21, 2014
- Chuikyo OKs NHI Price Listing of 14 APIs/15 Products
November 20, 2014
- MHLW Will Rack Its Brain about How to Eke Out Social Security Funds: Shiozaki
November 20, 2014
- 3 Straight Years of NHI Price Cuts Loom as Abe Delays Sales Tax Hike, Eyes Now Turned to 2019 and Beyond
November 19, 2014
- MHLW OKs 4 Products Including New Indication for Spiriva
November 19, 2014
- Health Ministry Drug Evaluation Head Calls for Mulling Necessity of PI Studies for Japanese Patients
November 18, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…